19:51 , Sep 7, 2018 |  BC Week In Review  |  Financial News

PhaseBio raises $34M series D

PhaseBio Pharmaceuticals Inc. (Malvern, Pa.) raised $34 million in a series D round from new investors Cormorant Asset Management, Rock Springs Capital and Mountain Group Partners. Existing investors New Enterprise Associates, Hatteras Venture Partners, AstraZeneca...
22:57 , Feb 2, 2018 |  BC Extra  |  Company News

AZ partners with Chinese internet giants, reports strong China sales

AstraZeneca plc (LSE:AZN; NYSE:AZN) announced two Chinese partnerships along with its 4Q17 earnings report Friday, which showed the company's sales in the country increased 30% at constant exchange rates to $813 million for the quarter. AZ...
23:32 , Nov 9, 2017 |  BC Extra  |  Company News

AZ reports strong China growth in earnings

In its 3Q17 earnings, AstraZeneca plc (LSE:AZN; NYSE:AZN) reported strong growth in the China market despite overall declining product sales. In China, sales were $723 million for the quarter, a 14% increase at constant exchange...
17:15 , Jun 2, 2017 |  BC Week In Review  |  Company News

AZ and Harvard Pilgrim sign two outcomes-based drug pricing contracts

Regional insurer Harvard Pilgrim Health Care Inc. (Boston, Mass.) signed two outcomes-based drug pricing contracts with AstraZeneca plc (LSE:AZN; NYSE:AZN). The insurer signed a three-year contract for AZ’s Brilinta ticagrelor, which is marketed in the U.S....
18:31 , Mar 31, 2017 |  BC Week In Review  |  Clinical News

Xarelto: Ph II GEMINI-ACS-1 data

The double-blind, international Phase II GEMINI-ACS-1 trial in 3,037 patients with ACS showed that twice-daily 2.5 mg oral Xarelto plus clopidogrel or Brilinta ticagrelor led to no significant difference in the rate of TIMI clinically...
22:20 , Jan 6, 2017 |  BioCentury  |  Finance

Tiers of disappointment

A bad year for biotech was closed with an even worse 4Q16 as volatility ahead of the U.S. elections and continued concerns around drug pricing held every market cap band in the red despite a...
16:16 , Nov 30, 2016 |  BC Week In Review  |  Clinical News

Pradaxa: Completed Ph III enrollment

Boehringer completed enrollment of 2,727 patients in the open-label, international Phase III RE-DUAL PCI trial comparing 110 and 150 mg oral Pradaxa twice daily plus clopidogrel or Brilinta ticagrelor vs. triple antithrombotic therapy comprising warfarin,...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Brilinta: Phase IIIb data

Top-line data from the double-blind, international Phase IIIb EUCLID trial in 13,885 symptomatic patients with PAD showed that twice-daily 90 mg oral Brilinta missed the primary endpoint of improving the time to first occurrence of...
07:00 , Oct 4, 2016 |  BC Extra  |  Clinical News

Brilinta not significantly better than clopidogrel in PAD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Brilinta ticagrelor missed the primary endpoint in the global Phase III EUCLID trial. The anticoagulant failed to significantly reduce major cardiovascular events in patients with peripheral arterial disease compared with...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Company News

AstraZeneca sales and marketing update

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment that there is “no added benefit” for Brilique ticagrelor from AstraZeneca in combination with a low-dose of aspirin to...